547 related articles for article (PubMed ID: 31856918)
1. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Rini BI; Battle D; Figlin RA; George DJ; Hammers H; Hutson T; Jonasch E; Joseph RW; McDermott DF; Motzer RJ; Pal SK; Pantuck AJ; Quinn DI; Seery V; Voss MH; Wood CG; Wood LS; Atkins MB
J Immunother Cancer; 2019 Dec; 7(1):354. PubMed ID: 31856918
[TBL] [Abstract][Full Text] [Related]
2. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Landscape of Immunotherapy-Based Combinations for Frontline Treatment of Advanced Renal Cell Carcinoma.
Amin A; Hammers H
Front Immunol; 2018; 9():3120. PubMed ID: 30687324
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
5. The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.
Salgia NJ; Dara Y; Bergerot P; Salgia M; Pal SK
Curr Treat Options Oncol; 2019 Apr; 20(5):41. PubMed ID: 30937639
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
7. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK; Kluger H; George S; Tykodi SS; Kuzel TM; Perets R; Nair S; Procopio G; Carducci MA; Castonguay V; Folefac E; Lee CH; Hotte SJ; Miller WH; Saggi SS; Lee CW; Desilva H; Bhagavatheeswaran P; Motzer RJ; Escudier B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328377
[TBL] [Abstract][Full Text] [Related]
8. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
9. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
12. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Tannir NM; Papadopoulos KP; Wong DJ; Aljumaily R; Hung A; Afable M; Kim JS; Ferry D; Drakaki A; Bendell J; Naing A
Int J Cancer; 2021 Jul; 149(2):403-408. PubMed ID: 33709428
[TBL] [Abstract][Full Text] [Related]
13. Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
Cao X; Tang D; Ratto B; Poole A; Ravichandran S; Jin L; Gao W; Swallow E; Vogelzang NJ
Clin Genitourin Cancer; 2020 Feb; 18(1):e37-e45. PubMed ID: 31727510
[TBL] [Abstract][Full Text] [Related]
14. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C
Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349
[TBL] [Abstract][Full Text] [Related]
15. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy.
Labbate C; Hatogai K; Werntz R; Stadler WM; Steinberg GD; Eggener S; Sweis RF
J Immunother Cancer; 2019 Mar; 7(1):66. PubMed ID: 30857555
[TBL] [Abstract][Full Text] [Related]
16. A review of checkpoint inhibitors in the management of renal cell carcinoma.
Hanna KS
J Oncol Pharm Pract; 2020 Mar; 26(2):445-458. PubMed ID: 31631812
[TBL] [Abstract][Full Text] [Related]
17. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Markham A
Target Oncol; 2022 Mar; 17(2):193-201. PubMed ID: 35175500
[TBL] [Abstract][Full Text] [Related]
18. Check point inhibitors a new era in renal cell carcinoma treatment.
Alsharedi M; Katz H
Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Massari F; Mollica V; Rizzo A; Cosmai L; Rizzo M; Porta C
Expert Opin Drug Saf; 2020 Oct; 19(10):1329-1338. PubMed ID: 32799582
[TBL] [Abstract][Full Text] [Related]
20. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
